We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $151.91, demonstrating a -0.69% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.38% for the day. On the other hand, the Dow registered a loss of 0.03%, and the technology-centric Nasdaq increased by 0.87%.
Heading into today, shares of the kidney dialysis provider had gained 6.9% over the past month, outpacing the Medical sector's loss of 3.56% and the S&P 500's loss of 5.59% in that time.
Investors will be eagerly watching for the performance of DaVita HealthCare in its upcoming earnings disclosure. The company's upcoming EPS is projected at $1.75, signifying a 26.47% drop compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $3.23 billion, showing a 5.27% escalation compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $10.76 per share and a revenue of $13.47 billion, representing changes of +11.16% and +5.08%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for DaVita HealthCare. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. DaVita HealthCare is currently a Zacks Rank #3 (Hold).
In terms of valuation, DaVita HealthCare is currently trading at a Forward P/E ratio of 14.21. This denotes a discount relative to the industry's average Forward P/E of 20.93.
Meanwhile, DVA's PEG ratio is currently 1.12. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. DVA's industry had an average PEG ratio of 2.13 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This group has a Zacks Industry Rank of 46, putting it in the top 19% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DaVita HealthCare (DVA) Stock Falls Amid Market Uptick: What Investors Need to Know
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $151.91, demonstrating a -0.69% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.38% for the day. On the other hand, the Dow registered a loss of 0.03%, and the technology-centric Nasdaq increased by 0.87%.
Heading into today, shares of the kidney dialysis provider had gained 6.9% over the past month, outpacing the Medical sector's loss of 3.56% and the S&P 500's loss of 5.59% in that time.
Investors will be eagerly watching for the performance of DaVita HealthCare in its upcoming earnings disclosure. The company's upcoming EPS is projected at $1.75, signifying a 26.47% drop compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $3.23 billion, showing a 5.27% escalation compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $10.76 per share and a revenue of $13.47 billion, representing changes of +11.16% and +5.08%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for DaVita HealthCare. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. DaVita HealthCare is currently a Zacks Rank #3 (Hold).
In terms of valuation, DaVita HealthCare is currently trading at a Forward P/E ratio of 14.21. This denotes a discount relative to the industry's average Forward P/E of 20.93.
Meanwhile, DVA's PEG ratio is currently 1.12. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. DVA's industry had an average PEG ratio of 2.13 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This group has a Zacks Industry Rank of 46, putting it in the top 19% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.